Bioactivation to an aldehyde metabolite-Possible role in the onset of toxicity induced by the anti-HIV drug abacavir

Toxicology Letters

Volumn 224, Issue 3, 2014, Pages 416-423

  Grilo, Nádia M ^a   Charneira, Catarina ^b   Pereira, Sofia A ^a   Monteiro, Emília C ^a   Marques, M Matilde ^b   Antunes, Alexandra M M ^b  

^a NOVA MEDICAL SCHOOL   (Portugal)

^b INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

Abacavir; Aldehyde metabolite; Cardiotoxicity; Drug bioactivation; Hypersensitivity reactions; Protein adducts

Indexed keywords

ABACAVIR; ACICLOVIR; ALDEHYDE; BORTEZOMIB; LACTACYSTIN;

ALLERGIC REACTION; ANTIVIRAL THERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY;

EID: 84890154590     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.10.036     Document Type: Review

References (73)

1. Adam J., Eriksson K.K., Schnyder B., Fontana S., Pichler W.J., Yerly D. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur. J. Immunol. 2012, 42:1706-1716.
2. AIDSinfo Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents 2013, Department of Health and Human Services, available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (accessed 16 July 2013).
3. Almeida C.-A.M., Martin A.M., Nolan D., Lucas A., Cameron P.U., James I., Phillips E., Mallal S. Cytokine profiling in abacavir hypersensitivity patients. Antivir. Ther. 2008, 13:281-288.
4. Behrens G.M.N., Reiss P. Abacavir and cardiovascular risk. Curr. Opin. Infect. Dis. 2010, 23:9-14.
5. Bélanger A., Pelletier G., Labrie F., Barbier O., Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol. Metab. 2003, 14:473-479.
6. Bell C.C., Castelazo A.S., Yang E.L., Maggs J.L., Jenkins R.E., Tugwood J., O'Neill P.M., Naisbitt D.J., Park B.K. Oxidative bioactivation of abacavir in subcellular fractions of human antigen presenting cells. Chem. Res. Toxicol. 2013, 26:1064-1072.
7. Bell C.C., Faulkner L., Martinsson K., Farrell J., Alfirevic A., Tugwood J., Pirmohamed M., Naisbitt D.J., Park B.K. T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms. Chem. Res. Toxicol. 2013, 26:759-766.
8. Bharadwaj M., Illing P., Kostenko L. Personalized medicine for HLA-associated drug-hypersensitivity reactions. Pers. Med. 2010, 7:495-516.
9. Bian Y., Chen Y.-g., Xu F., Xue L., Ji W.-q, Zhang Y. The polymorphism in aldehyde dehydrogenase-2 gene is associated with elevated plasma levels of high-sensitivity C-reactive protein in the early phase of myocardial infarction. Tohoku J. Exp. Med. 2010, 221:107-112.
10. Buhl R., Holroyd K.J., Mastrangeli A., Cantin A.M., Jaffe H.A., Wells F.B., Saltini C., Crystal R.G. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989, 334:1294-1298.
11. Charneira C., Godinho A.L.A., Oliveira M.C., Pereira S.A., Monteiro E.C., Marques M.M., Antunes A.M.M. Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity. Chem. Res. Toxicol. 2011, 24:2129-2141.
12. Charneira C., Grilo N.M., Pereira S.A., Godinho A.L.A., Monteiro E.C., Marques M.M., Antunes A.M.M. N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo. Br. J. Pharmacol. 2012, 167:1353-1361.
13. + T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008, 28:822-832.
14. Cheung C., Smith C.K., Hoog J.-O., Hotchkiss S.A.M. Expression and localization of human alcohol and aldehyde dehydrogenase enzymes in skin. Biochem. Biophys. Res. Commun. 1999, 261:100-107.
15. Cheung C., Davies N.G., Hoog J.-O., Hotchkiss S.A.M., Smith Pease C.K. Species variations in cutaneous alcohol dehydrogenases and aldehyde dehydrogenases may impact on toxicological assessments of alcohols and aldehydes. Toxicology 2003, 184:97-112.
16. Chittick G.E., Gillotin C., McDowell J.A., Lou Y., Edwards K.D., Prince W.T., Stein D.S. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 1999, 19:932-942.
17. Clay P.G. The abacavir hypersensitivity reaction: a review. Clin. Ther. 2002, 24:1502-1514.
18. Costagliola D., Lang S., Mary-Krause M., Boccara F. Abacavir and cardiovascular risk: reviewing the evidence. Curr. HIV/AIDS Rep. 2010, 7:127-133.
19. Daluge S.M., Good S.S., Faletto M.B., Miller W.H., St Clair M.H., Boone L.R., Tisdale M., Parry N.R., Reardon J.E., Dornsife R.E., Averett D.R., Krenitsky T.A. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 1997, 41:1082-1093.
20. Doser T.A., Turdi S., Thomas D.P., Epstein P.N., Li S.Y., Ren J. Transgenic overexpression of aldehyde dehydrogenase-2 rescues chronic alcohol intake-induced myocardial hypertrophy and contractile dysfunction. Circulation 2009, 119:1941-1949.
21. EACS European Guidelines for Treatment of HIV Infected Adults in Europe 2012, available at http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6.1-2edition.pdf (accessed 16 July 2013).
22. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11:81-128.
23. Estonius M., Danielsson O., Karlsson C., Person H., Jörnvall H., Höög J.O. Distribution of alcohol and sorbitol dehydrogenases. Assessment of mRNA species in mammalian tissues. Eur. J. Biochem. 1993, 215:497-503.
24. Faletto M.B., Miller W.H., Garvey E.P., St Clair M.H., Daluge S.M., Good S.S. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 1997, 41:1099-1107.
25. FDA FDA Drug Safety Communication: Safety Review Update of Abacavir and Possible Increased Risk of Heart Attack 2011, available at http://www.fda.gov/Drugs/DrugSafety/ucm245164.htm (accessed 16 July 2013).
26. Grilo N.M., Antunes A.M.M., Caixas U., Marinho A.T., Charneira C., Oliveira M.C., Monteiro E.C., Marques M.M., Pereira S.A. Monitoring abacavir bioactivation in humans: screening for an aldehyde metabolite. Toxicol. Lett. 2013, 219:59-64.
27. Gunness P., Aleksa K., Bend J., Koren G. Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite. Transl. Res. 2011, 158:290-301.
28. Guo R., Ren J. Alcohol and acetaldehyde in public health: from marvel to menace. Int. J. Environ. Res. Public Health 2010, 7:1285-1301.
29. Guo R., Ren J. Alcohol dehydrogenase accentuates ethanol-induced myocardial dysfunction and mitochondrial damage in mice: role of mitochondrial death pathway. PLoS One 2010, 5:e8757.
30. Guo Y., Shi L., Hong H., Su Z., Fuscoe J., Ning B. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci. China Life Sci. 2013, 56:119-124.
31. Hawkins T., Veikley W., St Claire R.L., Guyer B., Clark N., Kearney B.P. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 2005, 39:406-411.
32. Hervey P.S., Perry C.M. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 2000, 60:447-479.
33. Hintz K.K., Relling D.P., Saari J.T., Borgerding A.J., Duan J., Ren B.H., Kato K., Epstein P.N., Ren J. Cardiac overexpression of alcohol dehydrogenase exacerbates cardiac contractile dysfunction, lipid peroxidation, and protein damage after chronic ethanol ingestion. Alcohol. Clin. Exp. Res. 2003, 27:1090-1098.
34. Illing P.T., Vivian J.P., Dudek N.L., Kostenko L., Chen Z., Bharadwaj M., Miles J.J., Kjer-Nielsen L., Gras S., Williamson N.A., Burrows S.R., Purcell A.W., Rossjohn J., McCluskey J. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012, 486:554-558.
35. Islam F.M., Wu J., Jansson J., Wilson D.P. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012, 13:453-468.
36. Ismahil M.A., Hamid T., Haberzettl P., Gu Y., Chandrasekar B., Srivastava S., Bhatnagar A., Prabhu S.D. Chronic oral exposure to the aldehyde pollutant acrolein induces dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H2050-H2060.
37. Josephson R.A., Silverman H.S., Lakatta E.G., Stern M.D., Zweier J.L. Study of the mechanisms of hydrogen peroxide and hydroxyl free radical-induced cellular injury and calcium overload in cardiac myocytes. J. Biol. Chem. 1991, 266:2354-2361.
38. Kapetanovic I.M., Torchin C.D., Strong J.M., Yonekawa W.D., Lu C., Li A.P., Dieckhaus C.M., Santos W.L., Macdonald T.L., Sofia R.D., Kupferberg H.J. Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem. Biol. Interact. 2002, 142:119-134.
39. Leonarduzzi G., Robbesyn F., Poli G. Signaling kinases modulated by 4-hydroxynonenal. Free Radic. Biol. Med. 2004, 37:1694-1702.
40. Lockley D.J., Howes D., Williams F.M. Cutaneous metabolism of glycol ethers. Arch. Toxicol. 2005, 79:160-168.
41. Luo J., Hill B.G., Gu Y., Cai J., Srivastava S., Bhatnagar A., Prabhu S.D. Mechanisms of acrolein-induced myocardial dysfunction: implications for environmental and endogenous aldehyde exposure. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H3673-H3684.
42. Mallal S., Phillips E. Abacavir and the altered peptide repertoire model: clinical implications. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection. J. Int. AIDS Soc. 2012, 15(4):18119.
43. Mallal S., Phillips E., Carosi G., Molina J.M., Workman C., Tomažič J., Jägel-Guedes E., Rugina S., Kozyrev O., Flores Cid J., Hay P., Nolan D., Hughes S., Hughes A., Ryan S., Fitch N., Thorborn D., Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 2008, 358:568-579.
44. Martin A.M., Almeida C.-A., Cameron P., Purcell A.W., Nolan D., James I., McCluskey J., Phillips E., Landay A., Mallal S. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 2007, 21:1233-1244.
45. 14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents Chemother. 1999, 43:2855-2861.
46. Murray M.F., Nghiem M., Srinivasan A. HIV infection decreases intracellular nicotinamide adenine dinucleotide [NAD]. Biochem. Biophys. Res. Commun. 1995, 212:126-131.
47. Niemelä O. Distribution of ethanol-induced protein adducts in vivo: relationship to tissue injury. Free Radic. Biol. Med. 2001, 31:1533-1538.
48. Nishimura M., Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab. Pharmacokinet. 2006, 21:357-374.
49. Nising C.F., Bräse S. Recent developments in the field of oxa-Michael reactions. Chem. Soc. Rev. 2012, 41:988-999.
50. Nolan D. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit. Rev. Clin. Lab. Sci. 2009, 46:153-165.
51. Norcross M.A., Luo S., Lu L., Boyne M.T., Gomarteli M., Rennels A.D., Woodcock J., Margulies D.H., McMurtrey C., Vernon S., Hildebrand W.H., Buchli R. Abacavir induces loading of novel self-peptides into HLA-B*57:01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012, 26:F21-F29.
52. O'Brien P.J., Siraki A.G., Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit. Rev. Toxicol. 2005, 35:609-662.
53. Olson L.P., Luo J., Almarsson Ö., Bruice T.C. Mechanism of aldehyde oxidation catalyzed by horse liver alcohol dehydrogenase. Biochemistry 1996, 35:9782-9791.
54. Ostrov D.A., Grant B.J., Pompeu Y.A., Sidney J., Harndahl M., Southwood S., Oseroff C., Lu S., Jakoncic J., Oliveira C.A.F., Yang L., Mei H., Shi L., Shabanowitz J., English A.M., Wriston A., Lucas A., Phillips E., Mallal S., Grey H.M., Sette A., Hunt D.F., Buus S., Peters B. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:9959-9964.
55. Park S., Im S-A., Kim K-H., Lee C-K. Immunomodulatory effects of hypocrellin A on MHC-restricted antigen processing. Immune Netw. 2011, 11:412-415.
56. Pichler W.J., Naisbitt D.J., Park B.K. Immune pathomechanism of drug hypersensitivity reactions. J. Allergy Clin. Immunol. 2011, 127:S74-S81.
57. Ritter J.K. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact. 2000, 129:171-193.
58. Saag M., Balu R., Phillips E., Brachman P., Martorell C., Burman W., Stancil B., Mosteller M., Brothers C., Wannamaker P., Hughes A., Sutherland-Phillips D., Mallal S., Shaefer M., Study of Hypersensitivity to Abacavir Pharmacogenetic Evaluation Study Team High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 2008, 46:1111-1118.
59. Sabin C.A., Worm S.W., Weber R., Reiss P., El-Sadr W., Dabis F., De Wit S., Law M., Monforte A.D., Friis-Møller N., Kirk O., Pradier C., Weller I., Phillips A.N., Lundgren J.D. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417-1426.
60. Silverman R.B. The Organic Chemistry of Drug Design and Drug Action 2004, 617. Elsevier Academic Press, Burlington, MA. second ed.
61. Srivastava A., Maggs J.L., Antoine D.J., Williams D.P., Smith D.A., Park B.K. Role of reactive metabolites in drug-induced hepatotoxicity. Adverse Drug Reactions, Handbook of Experimental Pharmacology 2010, 165-194. Springer, Heidelberg. J. Uetrecht (Ed.).
62. Strubelt O., Brasch H., Pentz R., Younes M. Experimental studies on the acute cardiovascular toxicity of formalin and its antidotal treatment. J. Toxicol. Clin. Toxicol. 1990, 28:221-233.
63. Thompson M.A., Aberg J.A., Cahn P., Montaner J.S.G., Rizzardini G., Telenti A., Gatell J.M., Günthard H.F., Hammer S.M., Hirsch M.S., Jacobsen D.M., Reiss P., Richman D.D., Volberding P.A., Yeni P., Schooley R.T., International AIDS Society-USA Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. J. Am. Med. Assoc. 2010, 304:321-333.
64. Tolstrup J.S., Grønbæk M., Nordestgaard B.G. Alcohol intake, myocardial infarction, biochemical risk factors, and alcohol dehydrogenase genotypes. Circ. Cardiovasc. Genet. 2009, 2:507-514.
65. Townsend D.M., Tew K.D., Tapiero H. The importance of glutathione in human disease. Biomed. Pharmacother. 2003, 57:145-155.
66. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic. Biol. Med. 2000, 28:1685-1696.
67. Uetrecht J. Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metab. Rev. 2006, 38:745-753.
68. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol. 2007, 47:513-539.
69. Walsh J.S., Reese M.J., Thurmond L.M. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem. Biol. Interact. 2002, 142:135-154.
70. Weller S., Radomski K.M., Lou Y., Stein D.S. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 2000, 44:2052-2060.
71. Worm S.W., Sabin C., Weber R., Reiss P., El-Sadr W., Dabis F., De Wit S., Law M., D'Arminio Monforte A., Friis-Møller N., Kirk O., Fontas E., Weller I., Phillips A., Lundgren J. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 2010, 201:318-330. D:A:D Study Group.
72. Xie P.T., Hurley T.D. Methionine-141 directly influences the binding of 4-methylpyrazole in human σσ alcohol dehydrogenase. Protein Sci. 1999, 8:2639-2644.
73. Yuen G.J., Weller S., Pakes G.E. A review of the pharmacokinetics of abacavir. Clin. Pharmacokinet. 2008, 47:351-371.